Subconjunctival filtration in evolution: current evidence on MicroShunt implantation for treating patients with glaucoma

Ahmed I.I.K., Sadruddin O., Panarelli J.F.

2023
Eye and Vision

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

John Moran Eye Center, University of Utah, Salt Lake City, UT, United States; University of Toronto, Toronto, ON, Canada; Prism Eye Institute, Mississauga, ON, Canada; Santen Inc, Emeryville, CA, United States; New York University, New York, NY, United States

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.

Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022